T1	PROC 45 76	Estudio de eficacia y seguridad
T2	CHEM 80 89	ianalumab
T3	LIVB 93 102	pacientes
#1	AnnotatorNotes T3	C0030705; Patients; Patient or Disabled Group
T4	PROC 115 123	tratados
T5	PROC 203 250	Estudio de fase III, aleatorizado y doble ciego
T6	PROC 264 298	evalúan la eficacia y la seguridad
T7	CHEM 302 311	ianalumab
T8	CHEM 313 319	VAY736
T9	PROC 330 337	placebo
#2	AnnotatorNotes T9	C0032042; Placebos; Therapeutic or Preventive Procedure
T10	LIVB 341 350	pacientes
#3	AnnotatorNotes T10	C0030705; Patients; Patient or Disabled Group
T11	DISO 355 409	anemia hemolítica autoinmune por anticuerpos calientes
T12	DISO 411 416	AHAIc
T13	PROC 466 477	tratamiento
#4	AnnotatorNotes T13	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T14	DISO 500 554	Anemia hemolítica autoinmune por anticuerpos calientes
T15	DISO 556 561	AHAIc
T16	Age 591 598	18 años
T17	Age 607 612	o más
T18	PROC 636 650	consentimiento
T19	LIVB 654 667	Participantes
T20	PROC 759 790	prueba de antiglobulina directa
T21	DISO 891 898	recaído
T22	PROC 932 943	tratamiento
#5	AnnotatorNotes T22	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T23	LIVB 959 968	pacientes
#6	AnnotatorNotes T23	C0030705; Patients; Patient or Disabled Group
T24	DISO 986 997	dependencia
#7	AnnotatorNotes T24	C0439857; Dependence; Mental or Behavioral Dysfunction | C1510472; Drug Dependence; Mental or Behavioral Dysfunction
T25	DISO 1000 1012	intolerancia
T26	CHEM 1019 1029	esteroides
#8	AnnotatorNotes T26	C0038317; Steroids; Organic Chemical · Pharmacologic Substance
T27	PROC 1033 1061	Concentración de hemoglobina
T28	DISO 1115 1123	síntomas
#9	AnnotatorNotes T28	C1457887; Symptoms; Sign or Symptom
T29	DISO 1144 1150	anemia
#10	AnnotatorNotes T29	C0002871; Anemia; Disease or Syndrome
T30	PROC 1167 1189	tratamiento de soporte
T31	Duration 1215 1233	al menos 4 semanas
T32	PROC 1246 1260	aleatorización
#11	AnnotatorNotes T32	C0034656; Randomization; Research Activity
T33	Speculated 1268 1290	criterios de inclusión
T34	PROC 1305 1314	protocolo
#12	AnnotatorNotes T34	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T35	Spec_cue 1315 1321	pueden
T36	LIVB 1358 1367	Pacientes
#13	AnnotatorNotes T36	C0030705; Patients; Patient or Disabled Group
T37	DISO 1391 1414	enfermedad hematológica
#14	AnnotatorNotes T37	C0018939; Hematological Disease; Disease or Syndrome
T38	ANAT 1431 1442	médula ósea
#15	AnnotatorNotes T38	C0005953; Bone Marrow; Tissue
T39	DISO 1457 1460	LLC
#16	AnnotatorNotes T39	C0023434; Chronic Lymphocytic Leukemia; Neoplastic Process
T40	DISO 1469 1492	enfermedad inmunológica
#17	AnnotatorNotes T40	C0021053; Immune System Diseases; Disease or Syndrome
T41	PROC 1506 1535	tratamientos inmunosupresores
T42	Neg_cue 1540 1542	no
T43	Negated 1549 1559	permitidos
T44	DISO 1608 1612	AHAI
#18	AnnotatorNotes T44	C0002880; Autoimmune hemolytic anemia; Disease or Syndrome
T45	DISO 1647 1664	síndrome de Evans
#19	AnnotatorNotes T45	C0272126; Evans syndrome; Disease or Syndrome
T46	DISO 1673 1683	citopenias
#20	AnnotatorNotes T46	C0010828; Cytopenia; Pathologic Function
T47	PROC 1703 1736	terapia de depleción de células B
T48	CHEM 1743 1752	rituximab
#21	AnnotatorNotes T48	C0393022; rituximab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T49	PROC 1793 1807	aleatorización
#22	AnnotatorNotes T49	C0034656; Randomization; Research Activity
T50	PROC 1811 1822	Neutrófilos
T51	PROC 1836 1853	Creatinina sérica
#23	AnnotatorNotes T51	C0201976; Creatinine measurement, serum (procedure); Laboratory Procedure
T52	DISO 1909 1941	Infecciones víricas, bacterianas
T53	DISO 1983 1995	tuberculosis
#24	AnnotatorNotes T53	C0041296; Tuberculosis; Disease or Syndrome | C0041327; Tuberculosis, Pulmonary; Disease or Syndrome
T54	LIVB 1998 2008	SARS-CoV-2
#25	AnnotatorNotes T54	C5203676; SARS-CoV-2; Virus
T55	PROC 2024 2045	tratamiento sistémico
T56	DISO 2095 2106	infecciones
#26	AnnotatorNotes T56	C0009450; Communicable Diseases; Disease or Syndrome | C3714514; Infection; Pathologic Function
T57	DISO 2160 2183	infecciones bacterianas
#27	AnnotatorNotes T57	C0004623; Bacterial Infections; Disease or Syndrome
T58	DISO 2233 2256	virus de la hepatitis C
T59	PROC 2258 2298	antígeno de superficie de la hepatitis B
#28	AnnotatorNotes T59	C0201477; Hepatitis B surface antigen measurement; Laboratory Procedure
T60	PROC 2300 2305	HBsAg
#29	AnnotatorNotes T60	C0201477; Hepatitis B surface antigen measurement; Laboratory Procedure
T61	PROC 2309 2348	anticuerpo del núcleo de la hepatitis B
T62	PROC 2350 2355	HBcAb
T63	DISO 2386 2425	inmunodeficiencia primaria o secundaria
T64	PROC 2445 2449	test
#30	AnnotatorNotes T64	C0022885; Laboratory Procedures; Laboratory Procedure
T65	DISO 2462 2498	virus de la inmunodeficiencia humana
T66	DISO 2500 2503	HIV
T67	CHEM 2508 2533	Vacunas vivas o atenuadas
T68	PROC 2572 2586	aleatorización
#31	AnnotatorNotes T68	C0034656; Randomization; Research Activity
T69	PROC 2602 2615	esplenectomía
#32	AnnotatorNotes T69	C0037995; Splenectomy; Therapeutic or Preventive Procedure
T70	PROC 2659 2668	protocolo
#33	AnnotatorNotes T70	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T71	Spec_cue 2669 2675	pueden
T72	Date 12 16	2022
T73	DISO 128 182	anemia hemolítica autoinmune por anticuerpos calientes
T74	PROC 792 795	PAD
T75	PROC 797 832	específica para anti-IgG o anti-IgA
T76	DISO 1372 1377	AHAIc
T77	DISO 1638 1644	mixtas
T78	DISO 1618 1635	anticuerpos fríos
T79	PROC 1568 1575	estudio
T80	LIVB 2188 2211	organismos encapsulados
T81	DISO 1950 1961	infecciones
T82	DISO 672 677	AHAIc
T83	DISO 973 984	resistencia
T84	Duration 1766 1776	12 semanas
T85	Speculated 2676 2683	aplicar
T86	Duration 2546 2555	4 semanas
T87	Route 2036 2045	sistémico
T88	Observation 434 443	fracasado
T89	Quantifier_or_Qualifier 444 462	al menos una línea
T90	Quantifier_or_Qualifier 678 686	primaria
T91	Quantifier_or_Qualifier 689 699	secundaria
T92	Result_or_Value 734 752	resultado positivo
T93	Observation 860 882	respuesta insuficiente
T94	Quantifier_or_Qualifier 910 928	al menos una línea
T95	Observation 973 984	resistencia
T96	Result_or_Value 1078 1086	<10 g/dl
T97	CONC 1268 1290	criterios de inclusión
T98	Quantifier_or_Qualifier 1549 1559	permitidos
T99	Quantifier_or_Qualifier 1592 1597	otras
T100	Quantifier_or_Qualifier 1638 1644	mixtas
T101	Result_or_Value 1824 1833	<1000/mm3
T102	Result_or_Value 1854 1906	>1.5 por encima del límite superior de la normalidad
T103	Quantifier_or_Qualifier 1962 1969	activas
T104	Quantifier_or_Qualifier 2107 2134	clínicamente significativas
T105	Observation 2135 2146	recurrentes
T106	Quantifier_or_Qualifier 2199 2211	encapsulados
T107	Quantifier_or_Qualifier 2404 2412	primaria
T108	Quantifier_or_Qualifier 2415 2425	secundaria
T109	Result_or_Value 2450 2458	positivo
T110	CONC 2622 2644	criterios de exclusión
T111	Patient 93 102	pacientes
T112	History_of 115 123	tratados
T113	Patient 341 350	pacientes
T114	History_of 466 477	tratamiento
T115	History_of 479 485	VAYHIA
T116	Patient 654 667	Participantes
T117	History_of 932 943	tratamiento
T118	Patient 959 968	pacientes
T119	Patient 1358 1367	Pacientes
T120	History_of 1703 1736	terapia de depleción de células B
T121	History_of 1743 1752	rituximab
T122	History_of 2095 2106	infecciones
T123	History_of 2386 2425	inmunodeficiencia primaria o secundaria
T124	History_of 2462 2498	virus de la inmunodeficiencia humana
T125	History_of 2500 2503	HIV
T126	History_of 2602 2615	esplenectomía
